CPA
NVCR icon

Capital Performance Advisors’s NovoCure NVCR Stock Holding History

Capital Performance Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-35
Closed -$547 – 1825
2024
Q3 		$547 Buy
+35
New +$635 ﹤0.01% 2204

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Performance Advisors's NVCR Position: Q4 2024 in Review

Capital Performance Advisors sold out of NovoCure (NVCR) in Q4 2024, closing a stake of 35 shares — an estimated $547 sold.

Capital Performance Advisors first reported a position in NVCR in Q3 2024 and held it in 1 quarter. The position peaked at $547 in Q3 2024. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2024.

  • Capital Performance Advisors reported no remaining NovoCure position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 35 NovoCure shares in Q4 2024, an estimated $547.
  • Capital Performance Advisors first reported a position in NovoCure in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's NovoCure position peaked at $547 in Q3 2024.
  • 238 funds tracked by Wall St. Rank held NovoCure as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.